ELMIRON

This brand name is authorized in United States. It is also authorized in Austria, Canada, Croatia, Estonia, France, Ireland, Italy, Lithuania, Netherlands, Poland, Turkey, UK.

Active ingredients

The drug ELMIRON contains one active pharmaceutical ingredient (API):

1	Pentosan polysulfate UNII 914032762Y - PENTOSAN POLYSULFATE SODIUM
	The hypothetic mechanism of action of pentosan polysulfate includes a local effect in the bladder after systemic administration and excretion into the urine by binding of glycosaminoglycans to the deficient mucous of the bladder. It is hypothesized, that a potential barrier function of pentosan polysulfate instead of the damaged urothelial mucus might play a role as well the antiinflammatory activity of pentosan polysulfate sodium.
	Read more about Pentosan polysulfate

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ELMIRON Hard capsule	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
G04BX15	Pentosan polysulfate sodium	G Genito urinary system and sex hormones → G04 Urologicals → G04B Other urologicals, incl. antispasmodics → G04BX Other urologicals
Discover more medicines within G04BX15

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02029448
EE	Ravimiamet	1747560, 1789195, 1789207, 1863413
FR	Base de données publique des médicaments	60027685
GB	Medicines & Healthcare Products Regulatory Agency	356548, 357500
IT	Agenzia del Farmaco	045487016, 045487028, 045487030
LT	Valstybinė vaistų kontrolės tarnyba	1083165, 1083166, 1088298
NL	Z-Index G-Standaard, PRK	93904
PL	Rejestru Produktów Leczniczych	100391865
TR	İlaç ve Tıbbi Cihaz Kurumu	8699771000887
US	FDA, National Drug Code	50458-098